A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia

NCT02783573 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1722

Enrollment

INDUSTRY

Sponsor class

Stopped An independent assessment concluded the trial was not likely to meet the primary endpoint upon completion and therefore, trial stopped for futility.

Conditions

Alzheimer's Disease

Interventions

DRUG: Lanabecestat
DRUG: Placebo

Sponsor

AstraZeneca

Collaborators

[object Object]